Orforglipron is Eli Lilly’s once-daily GLP-1 pill, sold in the US as Foundayo. The FDA approved it for chronic weight management on April 1, 2026. Unlike Ozempic, Wegovy or the Wegovy pill, it is not a peptide. It’s a small molecule, so you can take it at any time of day, with or without food. In the 72-week ATTAIN-1 trial, people on the highest dose lost an average of 11.2% of their body weight, against 2.1% on placebo.
In Canada, it isn’t approved yet. Health Canada’s list of submissions under review shows orforglipron (from Eli Lilly Canada) accepted for review in January 2026, and no decision had been announced as of October 2026. In the US, self-pay prices run from $149 to $349 a month, depending on dose.
What is orforglipron?
Orforglipron is a GLP-1 receptor agonist. It acts on the same receptor as semaglutide (Ozempic, Wegovy) and as part of tirzepatide (Mounjaro, Zepbound). GLP-1 drugs reduce appetite, slow stomach emptying and help the body manage blood sugar. Orforglipron does this from a tablet you swallow once a day.
Its brand name in the US is Foundayo. It is approved for adults with obesity, or adults with overweight and at least one weight-related health condition, to reduce excess body weight and keep it off long term, alongside a reduced-calorie diet and more physical activity.
It’s worth being clear about what orforglipron is not. It isn’t a new kind of drug that works on more hormones than Ozempic does. It hits one target, the GLP-1 receptor, just like semaglutide. Drugs like tirzepatide (two targets) and retatrutide (three targets) are a different class. The breakthrough with orforglipron is how it’s delivered, not what it targets. For the multi-target drugs, see our guide to the next weight-loss drugs after Ozempic.
Small molecule, not a peptide: why it matters
Every other GLP-1 drug on the market is a peptide, a short chain of amino acids modelled on the body’s own GLP-1 hormone. Peptides have one big weakness as pills: stomach acid and digestive enzymes break them down. That’s why most GLP-1 drugs are injections.
The Wegovy pill gets around this with an added ingredient that protects semaglutide from some of that breakdown, but it has a cost. As Scientific American put it, the Wegovy pill must be taken on an empty stomach. Orforglipron is a non-peptide small molecule. It’s absorbed through the gut without breaking down, so it doesn’t come with the same food and water timing rules. Lilly markets it as a pill you can take at any time of day, with or without food.
Small molecules also matter for supply:
- Manufacturing. Small molecules are generally easier and cheaper to make than peptides. University of Toronto researcher Dr. Daniel Drucker put it this way: “Generally it’s much easier to make pills and distribute them.”
- Distribution. No cold chain and no injection pens. Dr. Deborah Horn of UTHealth Houston said it “gets rid of things like cold storage and plastics for [injection] pens.”
- Scale. GLP-1 drugs have faced shortages. A pill that’s easier to produce in large volumes could, in principle, reach more people.
If you’re curious about the peptide side of this, our Peptides 101 explains what peptides are and why most of them can’t simply be swallowed.
What the trials actually showed
Lilly ran a large phase 3 programme for orforglipron, with ATTAIN trials in obesity and ACHIEVE trials in type 2 diabetes. These are the results we could verify from published papers and company releases. The doses below are the ones each trial tested. They are trial facts, not treatment advice.
ATTAIN-1: obesity without diabetes
The ATTAIN-1 results were published in the New England Journal of Medicine in September 2025. The trial randomized 3,127 adults with obesity and without diabetes, in nine countries, to orforglipron 6 mg, 12 mg or 36 mg once daily, or placebo, for 72 weeks. Everyone also received diet and activity counselling.
| Group (ATTAIN-1, 72 weeks) | Average weight change |
|---|---|
| Orforglipron 6 mg | −7.5% |
| Orforglipron 12 mg | −8.4% |
| Orforglipron 36 mg | −11.2% |
| Placebo | −2.1% |
On the 36 mg dose, 55% of participants lost at least 10% of their body weight (vs 13% on placebo), and 19% lost at least 20% (vs 3%). Waist size, blood pressure, lipids and blood sugar all improved compared with placebo. Lilly’s headline figure, 12.4% (about 27 pounds), counts only people who stayed on treatment, which is why it’s higher than the 11.2% average for everyone randomized.
ATTAIN-2: obesity with type 2 diabetes
In more than 1,600 adults with obesity or overweight plus type 2 diabetes, the 36 mg dose produced 10.5% weight loss at 72 weeks, vs 2.2% on placebo. HbA1c fell by 1.3 to 1.8 points across doses, from a starting average of 8.1%.
ACHIEVE-1: early type 2 diabetes
ACHIEVE-1 (NEJM, June 2025) tested orforglipron on its own in 559 people with early type 2 diabetes for 40 weeks. HbA1c fell by 1.24 to 1.48 points on orforglipron vs 0.41 on placebo, and weight fell by 4.5% to 7.6% vs 1.7%.
ACHIEVE-3: head-to-head against the semaglutide pill
This is the trial that matters most for comparing pills. In 1,698 adults with type 2 diabetes on metformin, orforglipron (12 mg and 36 mg) was compared with oral semaglutide (7 mg and 14 mg) for 52 weeks. Orforglipron 36 mg lowered HbA1c by 2.2 points and weight by 9.2%. Oral semaglutide 14 mg lowered them by 1.4 points and 5.3%. One caveat: this trial tested lower doses of oral semaglutide than the 25 mg dose in the Wegovy pill, and it was open-label.
ATTAIN-MAINTAIN: switching from injections
Can a pill hold on to weight lost with an injection? ATTAIN-MAINTAIN took 376 people who had plateaued on Zepbound or Wegovy and switched them to orforglipron or placebo for 52 weeks. People switched from Wegovy kept all but about 0.9 kg of their weight loss compared with placebo. For people switched from Zepbound, the average difference vs placebo was 5.0 kg. That’s useful data on maintenance, but these were topline results from a company release.
FDA approval and the Foundayo name
The FDA approved Foundayo on April 1, 2026. It was the first new molecular entity approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) programme, a fast-track pilot. FiercePharma reported the FDA calling it the “fastest approval of a [new molecular entity] since 2002.” The programme is controversial: lawmakers have raised concerns about rushed reviews.
The approval rested on two randomized, double-blind, placebo-controlled trials showing significant weight loss vs placebo at 72 weeks. LillyDirect started shipping on April 6, 2026, with wider pharmacy and telehealth availability to follow. Two more points about the US status:
- The US approval covers weight management. Lilly’s submission for type 2 diabetes in the US was still pending as of October 2026.
- The marketed tablet strengths are numbered differently from the doses used in the trials, so don’t try to match trial numbers to pharmacy labels. Your prescriber handles that.
Outside the US, the UAE approved Foundayo earlier in 2026, and the UK’s MHRA approved it in August 2026. In October 2026, the EU’s CHMP recommended approval for both weight management and type 2 diabetes. Lilly says it has filed in about 40 markets worldwide.
How much Foundayo costs in the US
| How you pay (US) | Monthly price |
|---|---|
| Self-pay through LillyDirect | $149 (lowest dose) up to $349 (higher doses), USD |
| Commercial insurance + Lilly savings card | From $25 |
| Eligible Medicare Part D enrollees (from July 2026) | About $50 |
Those prices are in US dollars, apply only in the US, and come from Lilly as reported at launch. The lowest Foundayo price matches the lowest Wegovy pill price. Canadian pricing doesn’t exist yet, because the drug isn’t approved here.
Foundayo vs the Wegovy pill vs injections
This is the comparison most readers want. Read it with one warning: apart from ACHIEVE-3 (which tested lower doses of oral semaglutide in type 2 diabetes), these numbers come from different trials, with different people, lengths and methods. Novo Nordisk has called claims that Foundayo beats the Wegovy pill “inaccurate and misleading” because no head-to-head obesity trial exists.
| Foundayo (orforglipron) | Wegovy pill (oral semaglutide 25 mg) | Wegovy injection (semaglutide 2.4 mg) | |
|---|---|---|---|
| Molecule type | Small molecule (non-peptide) | Peptide + absorption enhancer | Peptide |
| How it’s taken | Daily tablet, any time, with or without food | Daily tablet on an empty stomach | Once-weekly injection pen |
| Key obesity trial | ATTAIN-1, 72 weeks | OASIS 4, 64 weeks | STEP 1, 68 weeks |
| Average weight loss vs placebo | 11.2% (36 mg) vs 2.1% | About 14% vs 2% | 14.9% vs 2.4% |
| Stopped for side effects | 5–10% vs 3% | 7% vs 6% | 4.5% stopped for GI effects vs 0.8% |
| FDA approval | April 1, 2026 | December 2025 | Yes (earlier) |
| US self-pay price | $149–$349/month | $149–$299/month | Varies |
| Health Canada status (Oct 2026) | Under review (accepted Jan 2026) | Submitted; no approval found | Approved (brand); generic Sevmia approved June 2026 |
Put simply, the Wegovy pill and injection have produced somewhat bigger average weight loss in their own trials. Foundayo’s advantages are convenience (no fasting rules), a manufacturing process that should be easier to scale, and the head-to-head ACHIEVE-3 win over lower-dose oral semaglutide. Novo also points out that among approved obesity drugs, only Wegovy has a proven cardiovascular risk-reduction claim.
Tirzepatide (Zepbound, Mounjaro) remains the stronger option for weight loss. As Dr. Horn said of Foundayo, “It’s not as high of weight loss as tirzepatide.” See retatrutide vs tirzepatide vs semaglutide for the injectable comparison. In Canada, generic injectable semaglutide is now much cheaper than the brand. See our generic Ozempic Canada guide.
Side effects and warnings
Orforglipron’s side effects look like those of other GLP-1 drugs. The ATTAIN-1 authors described the safety profile as consistent with the class, with gastrointestinal effects the most common, usually mild to moderate.
Common side effects (from the US label)
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Indigestion (dyspepsia)
In ATTAIN-1, 5% to 10% of people on orforglipron stopped because of side effects, vs about 3% on placebo. In ACHIEVE-3, 8.7% to 9.7% stopped on orforglipron vs 4.5% to 4.9% on oral semaglutide. So more people quit orforglipron in that trial, even though it worked better on average.
Label warnings
Like injectable GLP-1 drugs, Foundayo carries a boxed warning for thyroid C-cell tumours. The label also warns about:
- acute pancreatitis
- severe gastrointestinal reactions
- acute kidney injury from fluid loss
- low blood sugar
- serious allergic reactions
- diabetic retinopathy complications in people with type 2 diabetes
- gallbladder disease
- pulmonary aspiration during anesthesia
It shouldn’t be combined with another GLP-1 receptor agonist. Drucker’s caution applies to any new medicine: “Whenever we have a new medicine, we always restart the clock in terms of safety.”
Many of the questions people ask about Ozempic, like hair shedding or losing muscle along with fat, apply to any drug that causes fast weight loss. See hair loss on Ozempic and muscle loss on GLP-1 drugs.
Who it’s for
Based on its US approval, Foundayo is for adults with obesity, or with overweight plus at least one weight-related condition, alongside diet and activity changes. Its safety and effectiveness in children haven’t been established. In practice, a pill might suit people who:
- don’t want weekly injections, or are put off by needles
- find the Wegovy pill’s empty-stomach rules hard to follow day to day
- travel a lot, or don’t want to keep medication refrigerated
- have already lost weight on an injection and are looking at maintenance options with their doctor (the ATTAIN-MAINTAIN question)
Whether it’s right for you depends on your health history, other medications and goals. That’s for your doctor to decide. And for now, that conversation can’t end in a Canadian prescription.
Is Foundayo available in Canada?
Not yet. Here’s exactly what we could confirm as of October 2026:
- Health Canada’s official list of new drug submissions under review (current to August 31, 2026) includes “Orforglipron calcium” from Eli Lilly Canada Inc., accepted in January 2026. It’s classed as a new active substance under “Drugs used in diabetes,” and it’s flagged as part of an “aligned review” with a health technology assessment organization.
- A UK trade report from August 2026 also listed Canada as one of the countries still reviewing Foundayo.
- We found no Health Canada approval, Canadian brand launch or Canadian price.
When might it reach Canada?
Nobody has announced a date, so treat any specific month you see online with caution. What we know is that Health Canada’s performance standard for a new active substance is 300 calendar days to complete the first review. That clock pauses while the company answers Health Canada’s questions. Counting from a January 2026 acceptance, a decision in late 2026 or 2027 is plausible, but that is our estimate, not an official timeline. The “drugs used in diabetes” category also means the first Canadian approval could be for type 2 diabetes, weight management or both. We’ll update this page when Health Canada decides.
Until then, the GLP-1 options in Canada are injectable semaglutide (including the new generics), tirzepatide, and Rybelsus, the oral semaglutide for type 2 diabetes. The Wegovy pill is also still waiting on Health Canada: Novo said in January 2026 that its submission was under review. For what you can get today, see weight-loss injections in Canada.
Because orforglipron isn’t approved in Canada, anything sold here as “orforglipron” capsules, powder or tablets outside a pharmacy is unregulated, and you have no way of knowing what it actually contains. TrueLabs does not sell orforglipron. Our guide on how to spot fake peptides covers the warning signs.
Orforglipron myths
“Myth: Orforglipron is just Ozempic in pill form.”
No. Ozempic and the Wegovy pill contain semaglutide, a peptide. Orforglipron is a completely different, non-peptide molecule that happens to activate the same GLP-1 receptor.
“Myth: The pill works better than the injections.”
The trials don’t show that. Average weight loss in ATTAIN-1 (11.2%) was lower than in the injectable semaglutide trial STEP 1 (14.9%), and much lower than with tirzepatide. The pill’s advantage is convenience.
“Myth: Pills mean no side effects.”
The side effects are GLP-1 side effects, whatever the form. Nausea, vomiting, diarrhea and constipation were common, and Foundayo carries the same thyroid C-cell boxed warning as the injectables.
“Myth: Foundayo is approved in Canada because it’s approved in the US.”
FDA approval doesn’t carry over. Health Canada runs its own review, and as of October 2026 orforglipron was still on its under-review list.
“Myth: Orforglipron is a peptide you can buy for research.”
Orforglipron isn’t a peptide at all, and it isn’t part of TrueLabs’ catalogue.
For researchers
TrueLabs does not sell orforglipron or any approved drug. Our catalogue is peptide research reagents for in vitro and laboratory use only, not for human or veterinary use, and not a substitute for any prescription medicine.
For labs studying peptide incretin agonists, the comparison point for small-molecule work, TrueLabs supplies RT3 (retatrutide) from $90, a GIP/GLP-1/glucagon triple-agonist peptide, and TZ-2 (tirzepatide) from $73, a GIP/GLP-1 dual-agonist peptide. Background: retatrutide phase 3 results, tirzepatide research in Canada and the next weight-loss drugs after Ozempic. To check identity and purity, see How to read a peptide COA and the COA library.
FAQ
Tap a question to reveal the answer.
What is Foundayo?
Foundayo is the US brand name for orforglipron, Eli Lilly’s once-daily GLP-1 receptor agonist pill. The FDA approved it on April 1, 2026, for chronic weight management in adults with obesity, or with overweight and a weight-related condition. It can be taken at any time of day, with or without food.
Is orforglipron a peptide?
No. Orforglipron is a non-peptide small molecule. Semaglutide, tirzepatide and the other GLP-1 drugs are peptides. Because orforglipron isn’t broken down in the gut the way peptides are, it doesn’t need the fasting rules of the Wegovy pill.
How much weight did people lose on orforglipron?
In the 72-week ATTAIN-1 trial, average weight loss was 7.5%, 8.4% and 11.2% on the 6 mg, 12 mg and 36 mg doses, vs 2.1% on placebo. People with type 2 diabetes in ATTAIN-2 lost 10.5% on the highest dose, vs 2.2% on placebo. Results vary a lot between individuals.
Is Foundayo approved in Canada?
Not as of October 2026. Health Canada’s submissions-under-review list shows orforglipron from Eli Lilly Canada accepted for review in January 2026. No approval date or Canadian price has been announced.
When will the orforglipron pill come to Canada?
There is no official date. Health Canada’s standard for a first review of a new active substance is 300 calendar days, and the clock pauses while the company answers questions, so a decision in late 2026 or 2027 is plausible. That is an estimate, not a timeline from Lilly or Health Canada.
How much does Foundayo cost?
In the US, self-pay prices through LillyDirect run from $149 to $349 a month depending on dose. Commercially insured patients may pay from $25 with Lilly’s savings card. There is no Canadian price because it isn’t approved here.
Is Foundayo better than the Wegovy pill?
It depends on what you mean by better. In separate trials, the Wegovy pill produced larger average weight loss (about 14% at 64 weeks) than Foundayo (11.2% at 72 weeks). But Foundayo has no food or water rules and beat lower-dose oral semaglutide in the open-label ACHIEVE-3 diabetes trial. No head-to-head obesity trial exists.
What are the side effects of orforglipron?
The most common are nausea, constipation, diarrhea, vomiting and indigestion, usually mild to moderate. In ATTAIN-1, 5% to 10% of people stopped because of side effects, vs 3% on placebo. Foundayo carries a boxed warning for thyroid C-cell tumours, like other GLP-1 drugs.
Can I switch from Ozempic or Wegovy to orforglipron?
The ATTAIN-MAINTAIN trial studied people who switched from Wegovy or Zepbound and found that most of their weight loss was maintained compared with placebo. In Canada, orforglipron isn’t approved yet, so switching isn’t an option here. Talk to your doctor about your current options.
Does TrueLabs sell orforglipron?
No. TrueLabs doesn’t sell orforglipron, which is a small-molecule drug, not a peptide. We supply peptide research reagents such as RT3 and TZ-2 strictly for in vitro laboratory research.
Related reading
- The next weight-loss drugs after Ozempic
- Generic Ozempic in Canada
- Weight-loss injections in Canada
- Retatrutide vs tirzepatide vs semaglutide
- Retatrutide phase 3 results
- Peptides for weight loss
References
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025 (published online September 16, 2025). PubMed
- Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). N Engl J Med. 2025 (published online June 21, 2025). DOI
- Eli Lilly and Company. Lilly’s oral GLP-1 orforglipron delivered superior blood sugar and weight reductions vs oral semaglutide (ACHIEVE-3). Press release, February 26, 2026. investor.lilly.com
- Eli Lilly and Company. Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins (ATTAIN-MAINTAIN). Press release, December 18, 2025. investor.lilly.com
- HCPLive. Orforglipron delivers weight loss, A1c reductions in phase 3 ATTAIN-2 trial. August 26, 2025. hcplive.com
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
- FiercePharma. Lilly answers Novo’s GLP-1 pill with highly anticipated FDA nod for Foundayo. April 1, 2026. fiercepharma.com
- Scientific American. The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval. April 2, 2026. scientificamerican.com
- Drugs.com. Foundayo (orforglipron) FDA approval history and prescribing information summary. Updated May 2026. drugs.com
- Global News. Novo Nordisk launches Wegovy pill for sale in the U.S. January 6, 2026. Global News
- Health Canada. Drug and health product submissions under review: new drug submissions under review (current as of August 31, 2026). canada.ca
- Health Canada. Performance standards for the Fees in Respect of Drugs and Medical Devices Order. canada.ca
- Pharmaceutical Technology. Eli Lilly’s Foundayo weight loss pill gains MHRA approval. August 11, 2026. pharmaceutical-technology.com
- PharmExec. EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe. October 16, 2026. pharmexec.com
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.